Zai Lab Limited (ZLAB)
NASDAQ: ZLAB · Real-Time Price · USD
22.14
+0.26 (1.19%)
At close: Apr 28, 2026, 4:00 PM EDT
22.14
0.00 (0.00%)
After-hours: Apr 28, 2026, 5:02 PM EDT
Zai Lab Employees
Zai Lab had 1,784 employees as of December 31, 2025. The number of employees decreased by 85 or -4.55% compared to the previous year.
Employees
1,784
Change (1Y)
-85
Growth (1Y)
-4.55%
Revenue / Employee
$257,935
Profits / Employee
-$98,395
Market Cap
2.49B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| Ultragenyx Pharmaceutical | 1,371 |
| ADMA Biologics | 647 |
| Tarsus Pharmaceuticals | 370 |
| Vera Therapeutics | 249 |
| Celldex Therapeutics | 198 |
| Immunome | 177 |
| Disc Medicine | 155 |
| IDEAYA Biosciences | 145 |
ZLAB News
- 6 days ago - Zai Lab to Announce First Quarter 2026 Financial Results and Recent Corporate Updates on May 7, 2026 - Business Wire
- 8 days ago - Zai Lab Transcript: Study update - Transcripts
- 9 days ago - ZLAB: Zai Lab Unveils Promising Data for ZL-1503 in Treating Atopic Diseases - GuruFocus
- 10 days ago - Zai Lab Presents New Preclinical Data Suggesting ZL-1503, an IL-13/IL-31Rα Bispecific Antibody, Provides Rapid Itch Relief and Reduction in Inflammation in Atopic Diseases - Business Wire
- 11 days ago - ZLAB: Zai Lab Showcases Promising Clinical Data for Cancer Treatment - GuruFocus
- 11 days ago - Zai Lab Presents New Data Demonstrating Zocilurtatug Pelitecan (Zoci) Induces Rapid and Robust Intracranial Responses in Small Cell Lung Cancer with Brain Metastases and Promising Activity in Other Neuroendocrine Carcinomas - Business Wire
- 13 days ago - Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine Carcinomas - GlobeNewsWire
- 27 days ago - Zai Lab Stock Gains 8% Over Clinical Trial Collaboration With Amgen - Nasdaq